[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361435-105":59,"doc-detail-361435-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","grading-and-detecting-gastroenteropancreatic-neuroendocrine-neoplasms-with-dual-tracer-18f-alf-nota-octreotide18f-fdg-petct-a-metabolic-parameter-based-study","Grading and detecting gastroenteropancreatic neuroendocrine neoplasms with dual-tracer (18F-AlF-NOTA-octreotide/18F-FDG) PET/CT - a metabolic parameter-based study","","Dual-tracer 18F-AlF-NOTA-octreotide (18F-AlF-OC) and 18F-fluorodeoxyglucose (FDG) PET/CT are evaluated for grading gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). A retrospective cohort of 34 patients with 198 lesions compares quantitative metabolic indices, including SUVmax, TLG, SUVR, and the exploratory volumetric total lesion glycolysis ratio (TLGR). Diagnostic discrimination between G1/G2 versus G3/NEC and NET versus NEC is assessed using ROC, AUC and reclassification metrics. Results show complementary information, while incremental value of TLGR beyond SUVR and FDG SUVmax remains limited.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/grading-and-detecting-gastroenteropancreatic-neuroendocrine-neoplasms-with-dual-tracer-18f-alf-nota-octreotide18f-fdg-petct-a-metabolic-parameter-based-study/361435/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/grading-and-detecting-gastroenteropancreatic-neuroendocrine-neoplasms-with-dual-tracer-18f-alf-nota-octreotide18f-fdg-petct-a-metabolic-parameter-based-study/361435.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main objective of this study?","Question",{"text":113,"@type":114},"To evaluate quantitative metabolic indices from dual-tracer 18F-AlF-NOTA-octreotide and 18F-FDG PET/CT for grading gastroenteropancreatic neuroendocrine neoplasms, with emphasis on TLGR.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which PET/CT parameters were compared for grading performance?",{"text":118,"@type":114},"SUVmax, TLG, SUVR, and TLGR, where TLGR relates volumetric somatostatin receptor uptake on 18F-AlF-OC to 18F-FDG TLG.",{"name":120,"@type":111,"acceptedAnswer":121},"How well did TLGR improve diagnostic discrimination beyond other metabolic measures?",{"text":122,"@type":114},"Adding TLGR to SUVR or FDG SUVmax provided only modest improvement; TLGR showed limited incremental value, with reduced out-of-sample performance in cross-validation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},361435,1790173337,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Original article  \nGrading and detecting gastroenteropancreatic neuroendocrine neoplasms with dual-tracer ( 18 F-AlF-NOTA-octreotide/ 18 F-FDG) PET/CT: a metabolic parameter-based study  \nQing Dong, Qiuchen Zhou, Yang Liu, Qian Wang, Zhao Yang and Qian Su  \nObjective To evaluate quantitative metabolic indices from dual-tracer 18F-AlF-NOTA-octreotide (18F-AlF-OC) and 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) for grading gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), focusing on total lesion glycolysis ratio (TLGR).  \nMethods This retrospective study included 34 patients with GEP-NENs (198 target lesions) who underwent both 18F-AlF-OC and 18F-FDG PET/CT. Parameters included maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), SUV ratio (SUVR), and TLGR (ratio of 18F-AlF-OC volumetric somatostatin receptor uptake to 18F-FDG TLG by conventional TLG framework). Diagnostic performance for differentiating G1/G2 from G3/neuroendocrine carcinoma (NEC) and neuroendocrine tumor (NET) from NEC was assessed using receiver operating characteristic (ROC) analysis. Incremental value was evaluated using Δarea under the curve (AUC) and continuous net reclassification improvement with patientlevel cluster bootstrap resampling. Generalized estimating equation (GEE) models accounted for multiple lesions per patient. Internal validation used leave-one-patient-out cross-validation.  \nResults 18F-AlF-OC detected more lesions in G1/ G2 NETs, while detection was similar in NEC. In ROC analysis, TLGR, SUVR, and TLGR + SUVR yielded AUCs  \nIntroduction  \nNeuroendocrine neoplasms (NENs) are uncommon tumors originating from peptidergic neurons and neuroendocrine cells, with neuroendocrine differentiation and marker expression [1]. They may arise throughout the body, most frequently in the lungs and gastroenteropancreatic (GEP) system. Globally, the incidence of NENs has risen significantly in recent decades, particularly that of GEP-NENs [2]. According to the 2022 WHO classification system [3],  \nSupplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website, [www.nuclearmedicinecomm.com](www.nuclearmedicinecomm.com).  \nThis is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBYNC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nof 0. 760, 0. 760, and 0.767 for G1/G2 versus G3/NEC, and 0.811, 0.829, and 0.827 for NET versus NEC, respectively. Adding TLGR to SUVR or FDG SUVmax provided only modest improvement. TLGR was significant alone in GEE models but attenuated after SUVR adjustment, and crossvalidation showed reduced out-of-sample performance.  \nConclusion Dual-tracer PET/CT provides complementary information for GEP-NEN grading. TLGRis an exploratory volumetric dual-tracer parameter, but its incremental value beyond SUVR and FDG SUVmax is limited. Further validation is required. Nucl Med Commun 47: 1207–1217 Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, LLC.  \nNuclear Medicine Communications 2026, 47:1207–1217  \nKeywords: 18F-AlF-NOTA-octreotide, 18F-fluorodeoxyglucose, gastroenteropancreatic neuroendocrine neoplasms, PET, standardized uptake value ratio, total lesion glycolysis ratio  \nDepartment of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute & Hospital; Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin’s Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China  \nCorrespondence to Qian Su, MD, Department of Molecular Imaging and Nuclear Medicine, ","cbCaia7SjJLrGTC9","https://ap.wps.com/l/cbCaia7SjJLrGTC9","pdf",1763355,"English","# Objective\n# Methods\n## Study design and imaging parameters\n## Statistical analysis\n# Results\n# Conclusion\n# Background and context\n# Keywords","[{\"question\":\"What is the main objective of this study?\",\"answer\":\"To evaluate quantitative metabolic indices from dual-tracer 18F-AlF-NOTA-octreotide and 18F-FDG PET/CT for grading gastroenteropancreatic neuroendocrine neoplasms, with emphasis on TLGR.\"},{\"question\":\"Which PET/CT parameters were compared for grading performance?\",\"answer\":\"SUVmax, TLG, SUVR, and TLGR, where TLGR relates volumetric somatostatin receptor uptake on 18F-AlF-OC to 18F-FDG TLG.\"},{\"question\":\"How well did TLGR improve diagnostic discrimination beyond other metabolic measures?\",\"answer\":\"Adding TLGR to SUVR or FDG SUVmax provided only modest improvement; TLGR showed limited incremental value, with reduced out-of-sample performance in cross-validation.\"}]","Grading and detecting gastroenteropancreatic neuroendocrine neoplasms with dual-tracer (18F-AlF-NOTA-octreotide/18F-FDG) PET/CT - a metabolic parameter-based study | PDF",1790144287,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7211b26e22845e9b029ae052865382b1.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce0f3e20f90555ad43a2537fd59b5799.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e4be7ac09b3458eb33e05a1113aab19.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fb37574ea3de594afe07f856dc9c517.webp",980,1306]